Artificial Intelligence-suggested Predictive Model of Survival in Patients Treated With Stereotactic Radiotherapy for Early Lung Cancer
In Vivo · 2024
DOI: 10.21873/invivo.13576 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Paolo Borghetti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology Department, Spedali Civili and University of Brescia, Brescia, Italy. Hauptthemen laut MEDLINE: Radiosurgery, Lung Neoplasms, Artificial Intelligence. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: Overall survival (OS)-predictive models to clinically stratify patients with stage I Non-Small Cell Lung Cancer (NSCLC) undergoing stereotactic body radiation therapy (SBRT) are still unavailable. The aim of this work was to build a predictive model of OS in this setting. PATIENTS AND METHODS: Clinical variables of patients treated in three Institutions with SBRT for stage I NSCLC were retrospectively collected into a reference cohort A (107 patients) and 2 comparative cohorts B1 (32 patients) and B2 (38 patients). A predictive model was built using Cox regression (CR) and artificial neural networks (ANN) on reference cohort A and then tested on comparative cohorts. RESULTS: Cohort B1 patients were older and with worse chronic obstructive pulmonary disease (COPD) than cohort A. Cohort B2 patients were heavier smokers but had lower Charlson Comorbidity Index (CCI). At CR analysis for cohort A, only ECOG Performance Status 0-1 and absence of previous neoplasms correlated with better OS. The model was enhanced combining ANN and CR findings. The reference cohort was divided into prognostic Group 1 (0-2 score) and Group 2 (3-9 score) to assess model's predictions on OS: grouping was close to statistical significance (p=0.081). One and 2-year OS resulted higher for Group 1, lower for Group 2. In comparative cohorts, the model successfully predicted two groups of patients with divergent OS trends: higher for Group 1 and lower for Group 2. CONCLUSION: The produced model is a relevant tool to clinically stratify SBRT candidates into prognostic groups, even when applied to different cohorts. ANN are a valuable resource, providing useful data to build a prognostic model that deserves to be validated prospectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Oncology Department, Spedali Civili and University of Brescia, Brescia, Italy.
- Radiation Oncology Department, Humanitas-Gavazzeni, Bergamo, Italy.
- Azienda Ospedaliera Universitaria Integrata Verona, Radiation Oncology, Verona, Italy.
- Radiation Oncology Department, Spedali Civili and University of Brescia, Brescia, Italy; e.mataj@unibs.it.
- Radiotherapy Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
- Radiotherapy Unit, Ospedale del Mare, ASL Napoli 1, Naples, Italy.
Zitieren
APA
Borghetti, P., Costantino, G., Santoro, V., Mataj, E., Singh, N., Vitali, P., Greco, D., Volpi, G., Sepulcri, M., Guida, C., Tomasi, C., Buglione, M., & Nardone, V. (2024). Artificial Intelligence-suggested Predictive Model of Survival in Patients Treated With Stereotactic Radiotherapy for Early Lung Cancer. In Vivo. https://doi.org/10.21873/invivo.13576
Vancouver
Borghetti P, Costantino G, Santoro V, Mataj E, Singh N, Vitali P, et al. Artificial Intelligence-suggested Predictive Model of Survival in Patients Treated With Stereotactic Radiotherapy for Early Lung Cancer. In Vivo. 2024. doi:10.21873/invivo.13576
BibTeX
@article{Borghetti2024,
author = {Borghetti, Paolo and Costantino, Gianluca and Santoro, Valeria and Mataj, Eneida and Singh, Navdeep and Vitali, Paola and Greco, Diana and Volpi, Giulia and Sepulcri, Matteo and Guida, Cesare and Tomasi, Cesare and Buglione, Michela and Nardone, Valerio},
title = {Artificial Intelligence-suggested Predictive Model of Survival in Patients Treated With Stereotactic Radiotherapy for Early Lung Cancer},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13576}
}
EUVIMED